The FDA Has Cleared Tiziana Life Sciences' Investigational New Drug Application For Intranasal Foralumab To Be Studied In Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
The FDA has cleared Tiziana Life Sciences' Investigational New Drug Application for intranasal Foralumab to be studied in Alzheimer's disease. This is a significant step for Tiziana Life Sciences as it allows the company to proceed with clinical trials.
August 15, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences' Investigational New Drug Application for intranasal Foralumab has been cleared by the FDA. This allows the company to proceed with clinical trials, potentially leading to a new treatment for Alzheimer's disease.
The FDA clearance is a significant milestone for Tiziana Life Sciences as it allows the company to proceed with clinical trials for intranasal Foralumab. If successful, this could potentially lead to a new treatment for Alzheimer's disease, which would significantly boost the company's profile and potentially its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100